1.
Yong KL, Hinsley S, Auner HW, Bygrave C, Kaiser MF, Ramasamy K, de Tute RM, Sherratt D, Flanagan L, Garg M, Hawkins S, Williams C, Cavenagh J, Rabin NK, Croft J, Morgan G, Davies F, Owen RG, Brown SR. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i&gt;). haematol [Internet]. 2021Apr.29 [cited 2021Oct.19];106(10):2694-706. Available from: https://haematologica.org/article/view/haematol.2021.278399